Health care stocks were declining Thursday afternoon, with the NYSE Health Care Index shedding 0.4% and the Health Care Select Sector SPDR Fund (XLV) down 0.3%.
The iShares Biotechnology ETF (IBB) fell 1.1%.
In corporate news, Eli Lilly's (LLY) tirzepatide injection products Zepbound and Mounjaro are no longer in shortage, the US Food and Drug Administration said Thursday. Eli Lilly shares were down 0.8%.
Omeros (OMER) shares surged 44% after it said Thursday that its trial of narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy met its primary endpoint in overall survival.
Aquestive Therapeutics (AQST) shares jumped 5.6% after it said Thursday that its Libervant buccal film has received seven years of orphan drug exclusivity from the US Food and Drug Administration to treat seizure clusters in patients with epilepsy ages two to five.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。